Market research
TRVN Trevena Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 10K
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- -0.41
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US89532E1091
- Market cap
- 10K
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- -0.41
About
About Trevena Inc
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TRVN discussion.
5 years, 4 months ago
Trevena, Inc is currently in a long term downtrend where the price is trading 26.1% below its 200 day moving average.
From a valuation standpoint, the stock is 94.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 78.2.
Trevena, Inc's total revenue rose by 122.6% to $69K since the same quarter in the previous year.
Its net income has dropped by 84.2% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 5.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Trevena, Inc gets an overall score of 2/5.